AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19147137 — intervention group
Group type: EXPERIMENTAL
Intervention: PID patients with myeloperoxidase G/A alleles
Number of subjects: 44
Study 19147137 — intervention group
Group type: EXPERIMENTAL
Intervention: PID patients with G/G homozygous alleles
Number of subjects: 44
Study 19147137 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 44
Study 18476391 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg twice a day
Number of subjects: 60
Study 18476391 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine 100 mg/day
Number of subjects: 60
Study 18476391 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulphate tablet 100 mg (Control)
Number of subjects: 60
Study 15650846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (IM up to 3 days, then oral 40-80 mg, b.i.d.)
Number of subjects: 565
Study 15650846 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (IM up to 3 days, then oral 5-20 mg/day)
Number of subjects: 565
Study 12105288 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Watchers program
Number of subjects: 48
Study 12105288 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized approach
Number of subjects: 48
Study 12105288 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive group (individualized counseling + Weight Watchers)
Number of subjects: 48
Study 12105288 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study 10431068 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 40
Study 10431068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 40
Study 10431068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 40
Study 10431068 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate (ATP)
Number of subjects: 40
Study 10431068 — intervention group
Group type: COMPARATOR
Intervention: All groups (including physical exercise, dobutamine, dipyridamole, ATP)
Number of subjects: 40
Study 7552502 — intervention group
Group type: EXPERIMENTAL
Intervention: IDUs enrolled in the HIV vaccine trial
Number of subjects: 119
Study 7552502 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up visits for IDUs
Number of subjects: 119
Study 2349198 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised fenoterol (5 mg)
Number of subjects: 12
Study 2349198 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol (5 mg)
Number of subjects: 12
Study 2349198 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised terbutaline (5 mg)
Number of subjects: 12
Study 2349198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 387495 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% betamethasone dipropionate cream
Number of subjects: 62
Study 387495 — intervention group
Group type: COMPARATOR
Intervention: 0.025% fluocinolone acetonide cream
Number of subjects: 62
Study 31714121 — intervention group
Group type: EXPERIMENTAL
Intervention: Afrikaans language communication skills classes
Number of subjects: 600
Study 31714121 — intervention group
Group type: EXPERIMENTAL
Intervention: Xhosa language communication skills classes
Number of subjects: 600
Study 31714121 — intervention group
Group type: EXPERIMENTAL
Intervention: Second language learning
Number of subjects: 600
Study 28482738 — intervention group
Group type: EXPERIMENTAL
Intervention: DMARD + Adalimumab (ADA), n = 42
Number of subjects: 80
Study 28482738 — intervention group
Group type: COMPARATOR
Intervention: DMARD + Placebo (PLA), n = 38
Number of subjects: 80
Study 28482738 — intervention group
Group type: COMPARATOR
Intervention: Healthy Volunteers (HV), n = 40
Number of subjects: 80
Study 28482738 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall RA patients (DMARD + ADA and DMARD + PLA)
Number of subjects: 80
Study 25562265 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (n=711) aimed at achieving glycemia as close to the nondiabetic range as safely possible.
Number of subjects: 1441
Study 25562265 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (n=730) with the goal of avoiding symptomatic hypoglycemia and hyperglycemia.
Number of subjects: 1441
Study 25562265 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of glycated hemoglobin (HbA1c)
Number of subjects: 1441
Study 25562265 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of albuminuria
Number of subjects: 1441
Study 23631512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 142
Study 23631512 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-Sulbactam (Unasyn)
Number of subjects: 142
Study 21991730 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.3 mg kg(‐1)
Number of subjects: 30
Study 21991730 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study 19023657 — intervention group
Group type: EXPERIMENTAL
Intervention: Project MYTRI intervention activities (peer-led classroom activities involving games, competitions, etc.)
Number of subjects: 0
Study 19023657 — intervention group
Group type: EXPERIMENTAL
Intervention: Project MYTRI intervention activities
Number of subjects: 0
Study 16960411 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol therapy (6.25 mg/day uptitrated to 23.9 +/- 13.9 mg)
Number of subjects: 31
Study 16960411 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 patients, mean age 69.4 years, unable to take carvedilol)
Number of subjects: 31
Study 12670065 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home treatment with 10% carbamide peroxide
Number of subjects: 0
Study 12670065 — intervention group
Group type: COMPARATOR
Intervention: In-office treatment with 35% hydrogen peroxide
Number of subjects: 0
Study 12670065 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home treatment
Number of subjects: 0
Study 12670065 — intervention group
Group type: COMPARATOR
Intervention: In-office treatment
Number of subjects: 0
Study 12670065 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study 10968244 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin and iron supplementation
Number of subjects: 0
Study 10968244 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9366101 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline
Number of subjects: 131
Study 9366101 — intervention group
Group type: COMPARATOR
Intervention: Naftidrofuryl
Number of subjects: 131
Study 1555086 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐ketoisocaproate (17 g day‐1)
Number of subjects: 24
Study 1555086 — intervention group
Group type: EXPERIMENTAL
Intervention: branched chain solution (3.3 g nitrogen day‐1)
Number of subjects: 24
Study 1555086 — intervention group
Group type: COMPARATOR
Intervention: balanced amino acid solution (no further supplements)
Number of subjects: 24
Study 3104657 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 600 micrograms nocte
Number of subjects: 203
Study 3104657 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg nocte
Number of subjects: 203
Study 30769358 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 31272834 — intervention group
Group type: EXPERIMENTAL
Intervention: Mokuboito plus standard therapy
Number of subjects: 40
Study 31272834 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 40
Study 28877862 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tailored intervention with virtual assistants
Number of subjects: 8062
Study 28877862 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard information)
Number of subjects: 8062
Study 26301603 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of antihypertensive treatment (n=199)
Number of subjects: 385
Study 26301603 — intervention group
Group type: COMPARATOR
Intervention: Continuation of antihypertensive treatment (n=186)
Number of subjects: 385
Study 26301603 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of antihypertensive treatment
Number of subjects: 385
Study 23839180 — intervention group
Group type: EXPERIMENTAL
Intervention: Duac® Gel (BPO 5%‐clindamycin phosphate 1.2%)
Number of subjects: 0
Study 23839180 — intervention group
Group type: EXPERIMENTAL
Intervention: Acanya® Gel (BPO 2.5%‐clindamycin phosphate 1.2%)
Number of subjects: 0
Study 23839180 — intervention group
Group type: EXPERIMENTAL
Intervention: Aczone® Gel (dapsone 5%)
Number of subjects: 0
Study 23839180 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiduo® Gel (BPO 2.5%‐adapalene 0.1%)
Number of subjects: 0
Study 23839180 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 0
Study 21631510 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + EMD
Number of subjects: 12
Study 21631510 — intervention group
Group type: COMPARATOR
Intervention: CAF + CTG
Number of subjects: 12
Study 19538082 — intervention group
Group type: EXPERIMENTAL
Intervention: Systems Training for Emotional Predictability and Problem Solving (STEPPS)
Number of subjects: 0
Study 19538082 — intervention group
Group type: COMPARATOR
Intervention: BEST scale
Number of subjects: 0
Study 16440121 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized terbutaline plus intravenous betamethasone
Number of subjects: 22
Study 16440121 — intervention group
Group type: COMPARATOR
Intervention: Nebulized terbutaline alone (control)
Number of subjects: 22
Study 15571785 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused psychoeducational treatment for bipolar adolescents (FFT-A) combined with mood stabilizing medications
Number of subjects: 20
Study 11810324 — intervention group
Group type: EXPERIMENTAL
Intervention: Harpagophytum extract LI 174 (Rivoltan(R)) 2x480 mg/day for 4 weeks
Number of subjects: 63
Study 11810324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 9020324 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric drainage (ED)
Number of subjects: 46
Study 9020324 — intervention group
Group type: COMPARATOR
Intervention: Bladder drainage (BD)
Number of subjects: 46
Study 7885976 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased contact with pharmacists
Number of subjects: 0
Study 7885976 — intervention group
Group type: COMPARATOR
Intervention: Usual pharmacy care with minimum contact
Number of subjects: 0
Study 3257749 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% dexamethasone phosphate, topically applied four times a day for 7 days
Number of subjects: 13
Study 3257749 — intervention group
Group type: COMPARATOR
Intervention: Placebo, topically applied to contralateral eye
Number of subjects: 13
Study 3257749 — intervention group
Group type: COMPARATOR
Intervention: Comparison between dexamethasone and placebo
Number of subjects: 13
Study 31379271 — intervention group
Group type: COMPARATOR
Intervention: Smile Connect (SC) programme for older adults; twelve 30-minute chat sessions conducted via Skype over six weeks.
Number of subjects: 94
Study 31379271 — intervention group
Group type: COMPARATOR
Intervention: Smile Connect (SC) programme for young adults; twelve 30-minute chat sessions conducted via Skype over six weeks.
Number of subjects: 94
Study 29311137 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7325 (4‐amino‐8‐(2‐fluoro‐6‐methoxyphenyl)‐N‐propylcinnoline‐3‐carboxamide) administered orally, repeated doses over a period not specified.
Number of subjects: 0
Study 26667151 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training
Number of subjects: 31
Study 26667151 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 25342205 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX 1.0 µg/kg 5 min before propofol injection (group VII)
Number of subjects: 210
Study 25342205 — intervention group
Group type: COMPARATOR
Intervention: Control group (isotonic saline, group I)
Number of subjects: 210
Study 23329121 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcorneal electrical stimulation (TES) at 66% of the individual electrically stimulated phosphene threshold
Number of subjects: 12
Study 23329121 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcorneal electrical stimulation (TES) at 150% of the individual electrically stimulated phosphene threshold
Number of subjects: 12
Study 23329121 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (0% stimulation)
Number of subjects: 12
Study 22145513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramtace 10 mg (test product)
Number of subjects: 24
Study 19828901 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 322
Study 19828901 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 322
Study 19828901 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 322
Study 19828901 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 322
Study 19828901 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss at month-6
Number of subjects: 322
Study 19828901 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline BMI
Number of subjects: 322
Study 19828901 — intervention group
Group type: EXPERIMENTAL
Intervention: Less weight loss at month-6
Number of subjects: 322
Study 16289360 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women
Number of subjects: 80
Study 16289360 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with EPDS scores >9 points (maternal depression)
Number of subjects: 80
Study 16289360 — intervention group
Group type: COMPARATOR
Intervention: Non-pregnant women (control group)
Number of subjects: 80
Study 14767603 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fat interposition between the dura mater and spinous process of L5
Number of subjects: 178
Study 14767603 — intervention group
Group type: COMPARATOR
Intervention: No epidural fat interposition (Control group)
Number of subjects: 178
Study 10981566 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microg/ml sufentanil
Number of subjects: 243
Study 10981566 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 microg/ml sufentanil
Number of subjects: 243
Study 10981566 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg/ml sufentanil
Number of subjects: 243
Study 9024262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovine CRH (oCRH) injection during desmopressin (DP) infusion
Number of subjects: 6
Study 9024262 — intervention group
Group type: COMPARATOR
Intervention: Ovine CRH (oCRH) injection during saline (SAL) infusion
Number of subjects: 6
Study 9024262 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (DP) infusion plus SAL injection
Number of subjects: 6
Study 9024262 — intervention group
Group type: COMPARATOR
Intervention: SAL injection during SAL infusion
Number of subjects: 6
Study 8453023 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron administered orally at doses ranging from 50 to 400 mg (mesylate monohydrate)
Number of subjects: 0
Study 8453023 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dolasetron metabolite
Number of subjects: 0
Study 3142400 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg/day
Number of subjects: 30
Study 3142400 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg/day
Number of subjects: 30
Study 3142400 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (at D 90)
Number of subjects: 30
Study 3142400 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 29320595 — intervention group
Group type: EXPERIMENTAL
Intervention: 1060 nm laser treatment
Number of subjects: 35
Study 27177041 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC) intervention
Number of subjects: 100
Study 27177041 — intervention group
Group type: COMPARATOR
Intervention: Education control
Number of subjects: 100
Study 25716899 — intervention group
Group type: EXPERIMENTAL
Intervention: SCORES intervention
Number of subjects: 460
Study 23761964 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% GCV in situ ophthalmic gel
Number of subjects: 0
Study 23761964 — intervention group
Group type: COMPARATOR
Intervention: 0.15% GCV ophthalmic gel (control)
Number of subjects: 0
Study 17058824 — intervention group
Group type: EXPERIMENTAL
Intervention: Shexiang Baoxin Pill (SBP) plus routine treatment
Number of subjects: 41
Study 17058824 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment only (Control)
Number of subjects: 41
Study 12938897 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group with different instructional communication methods
Number of subjects: 174
Study 12938897 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard communication methods
Number of subjects: 174
Study 10804656 — intervention group
Group type: EXPERIMENTAL
Intervention: New methods of diagnostic imaging and staging invasive procedures
Number of subjects: 0
Study 10804656 — intervention group
Group type: COMPARATOR
Intervention: Different treatments evaluated in randomized trials
Number of subjects: 0
Study 8669331 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefminox
Number of subjects: 22
Study 8669331 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 22
Study 2107242 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) nebulizer solution 1% administered three to four times daily for 8 weeks
Number of subjects: 14
Study 2107242 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered for 8 weeks
Number of subjects: 14
Study 447899 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic beverage
Number of subjects: 32
Study 447899 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholic beverage
Number of subjects: 32
Study 447899 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation of alcohol
Number of subjects: 32
Study 447899 — intervention group
Group type: COMPARATOR
Intervention: No expectation of alcohol
Number of subjects: 32
Study 30854874 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 40
Study 30854874 — intervention group
Group type: COMPARATOR
Intervention: Inactive control
Number of subjects: 40
Study 29773662 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 212
Study 29773662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 26661693 — intervention group
Group type: EXPERIMENTAL
Intervention: AD-ON risk score
Number of subjects: 11140
Study 25711404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 1199
Study 25711404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1199
Study 23294801 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 591
Study 23294801 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 5 mg
Number of subjects: 591
Study 19582579 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg once daily
Number of subjects: 206
Study 19582579 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 206
Study 19582579 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label lansoprazole therapy (dose-titrated)
Number of subjects: 206
Study 17884925 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion into biceps brachii
Number of subjects: 0
Study 16463863 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (mild hypothermia group: 32‐34 degrees C, n = 10; very mild hypothermia group: 35‐36 degrees C, n = 10)
Number of subjects: 20
Study 16463863 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapeutic hypothermia)
Number of subjects: 20
Study 16463863 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (32‐34 degrees C)
Number of subjects: 20
Study 16463863 — intervention group
Group type: EXPERIMENTAL
Intervention: Very mild hypothermia (35‐36 degrees C)
Number of subjects: 20
Study 12027846 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 60
Study 12027846 — intervention group
Group type: COMPARATOR
Intervention: Tracheal Tube (TT)
Number of subjects: 60
Study 10323377 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-6 mg/day lacidipine
Number of subjects: 40
Study 10323377 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-20 mg/day lisinopril
Number of subjects: 40
Study 7795341 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate
Number of subjects: 180
Study 7795341 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 180
Study 1875248 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder movement
Number of subjects: 6
Study 1875248 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger opposition
Number of subjects: 6
Study 1875248 — intervention group
Group type: EXPERIMENTAL
Intervention: Fist-making
Number of subjects: 6
Study 1875248 — intervention group
Group type: EXPERIMENTAL
Intervention: Index finger movement
Number of subjects: 6
Study 6271814 — intervention group
Group type: EXPERIMENTAL
Intervention: THC, 5 mg
Number of subjects: 120
Study 6271814 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 120
Study 6271814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 6271814 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine (PCPZ), 10 mg
Number of subjects: 120
Study 6271814 — intervention group
Group type: EXPERIMENTAL
Intervention: THC, 10 mg
Number of subjects: 120
Study 6271814 — intervention group
Group type: EXPERIMENTAL
Intervention: THC, 15 mg
Number of subjects: 120
Study 31283756 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide, Moxifloxacin (potassium channel blockers)
Number of subjects: 44
Study 31283756 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine, Lidocaine (sodium or calcium channel blockers)
Number of subjects: 44
Study 31283756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (multichannel blocking drug)
Number of subjects: 44
Study 31283756 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide + Mexiletine, Dofetilide + Lidocaine (drug combinations)
Number of subjects: 44
Study 31283756 — intervention group
Group type: EXPERIMENTAL
Intervention: Tr40c (parameter for differentiating drugs)
Number of subjects: 44